BioCentury | Oct 31, 2011
Company News

Ethypharm, Lansen Pharmaceutical sales and marketing update

...Ethypharm granted Lansen's Ningbo Lansen Pharmaceutical Co. Ltd. subsidiary exclusive rights to commercialize ketoprofen/omeprazole in China...
...not disclosed. Meda AB (SSE:MEDAA, Solna, Sweden) has rights to market the compound, known as Axorid...
BioCentury | Jan 11, 2010
Company News

Ethypharm, Meda sales and marketing update

...Russian and Turkish rights to a 2007 deal granting Meda exclusive rights to market Ethypharm's Axorid...
BioCentury | Jan 5, 2009
Finance

4Q approvals

...who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy Meda (SSE:MEDA)/Ethypharm U.K. approves ketoprofen/omeprazole...
BioCentury | Dec 15, 2008
Clinical News

Ketoprofen/omeprazole regulatory update

...Meda AB (SSE:MEDA, Solna, Sweden) said the U.K. approved the company's ketoprofen/omeprazole combination product to treat...
BioCentury | Dec 10, 2008
Company News

U.K. approves ketoprofen/omeprazole combination

Meda (SSE:MEDA) said the U.K. approved the company's ketoprofen/ omeprazole combination product to treat pain and inflammation. The combination of an NSAID and a proton pump inhibitor (PPI) is under review in several other European...
BioCentury | Aug 13, 2007
Company News

Ethypharm, Meda deal

...MEDA received exclusive rights to market a ketoprofen/omeprazole combination product in certain European territories to treat...
Items per page:
1 - 6 of 6